Bruno Nardo1, Simone Serafini2, Michele Ruggiero3, Raffaele Grande4, Francesco Fugetto5, Alessandra Zullo6, Matteo Novello7, Antonia Rizzuto8, Elisabetta Bonaiuto9, Sebastiano Vaccarisi10, Giuseppe Cavallari11, Raffaele Serra12, Marco Cannistrà13, Rosario Sacco14. 1. Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Italy; Department of Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy. Electronic address: Bruno.nardo@unibo.it. 2. Department of Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy. Electronic address: seraf87@gmail.com. 3. Department of Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy. Electronic address: ruggant@alice.it. 4. Department of Medical and Surgical Sciences, University of Catanzaro, Italy. Electronic address: raffaele.eia@alice.it. 5. Department of Medical and Surgical Science, University of Modena, Italy. Electronic address: francescofugetto@gmail.com. 6. Department of Medical and Surgical Sciences, University of Catanzaro, Italy. Electronic address: alessandra.zullo@gmail.com. 7. Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Italy. Electronic address: matteo.novello@studio.unibo.it. 8. Department of Medical and Surgical Sciences, University of Catanzaro, Italy. Electronic address: arizzuto@unicz.it. 9. Department of Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy. Electronic address: bonaiutoelisabetta@gmail.com. 10. Department of Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy. Electronic address: s.vaccarisi@libero.it. 11. Department of Experimental Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, University of Bologna, Italy. Electronic address: giuseppe.cavallari3@unibo.it. 12. Department of Experimental Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, University of Bologna, Italy. Electronic address: rserra@unicz.it. 13. Department of Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy. Electronic address: anubis_m@libero.it. 14. Department of Medical and Surgical Sciences, University of Catanzaro, Italy. Electronic address: sacco@unicz.it.
Abstract
INTRODUCTION AND AIM: Patients with colorectal cancer (CRC) may develop liver metastases. Surgical resection remains the best treatment of choice for colorectal liver metastases (CRLM) according to resectability criteria, with a long-term survival of 25% up to 41% after 5 years. Advanced age is associated with a higher incidence and co-morbidity, particularly cardiovascular disease, as well as deteriorating physiological reserves. The aim of this study was to analyse the overall and disease-free survival for patients with CRLM according to their chronological age. METHODS: Patients with CRLM were enrolled in the study. Data on gender, age, co-morbidity, metastasis characteristics (number, size and total metastatic volume (TMV)), use of perioperative chemotherapy and operative and post-operative complications were collected. Then, according to recent World Health Organization (WHO) guidelines, the patients were grouped by age. Statistical analysis was performed using the software R (ver. 2.14.1). RESULTS: Hepatic resection was performed in 149 patients (21 patients in the very elderly group, 79 in the elderly group and 49 in the younger group). The three groups were comparable in terms of operative duration, transfusion rate, length of high-dependency unit (HDU) stay and post-operative hospital stay. The very elderly group showed a non-significant increase in post-operative morbidity. The 30-day and 60-day/inpatient mortality rates increased with age without any significant statistically difference between the three groups (very elderly group 4.8% and 4.8%; elderly group: 2.5% and 3.8%; and younger group 0% and 2%). At 5 years, the overall survival was 28.6% for very elderly patients (≥75 years), 33.3% for elderly patients (≥65 to <75 years) and 43.5% for younger patients (≤65 years). The 1-, 3- and 5-year disease-free survival was similar across the groups. CONCLUSIONS: Liver resection for CRLM in carefully selected patients above the age of 75 can be performed with acceptable morbidity and mortality rates, similar to those in younger patients. Moreover, the severity of CRLM in elderly patients is proven to be lesser than in younger patients. Thus, we can conclude that advanced chronological age cannot be considered a contraindication to hepatic resection for CRLM.
INTRODUCTION AND AIM: Patients with colorectal cancer (CRC) may develop liver metastases. Surgical resection remains the best treatment of choice for colorectal liver metastases (CRLM) according to resectability criteria, with a long-term survival of 25% up to 41% after 5 years. Advanced age is associated with a higher incidence and co-morbidity, particularly cardiovascular disease, as well as deteriorating physiological reserves. The aim of this study was to analyse the overall and disease-free survival for patients with CRLM according to their chronological age. METHODS:Patients with CRLM were enrolled in the study. Data on gender, age, co-morbidity, metastasis characteristics (number, size and total metastatic volume (TMV)), use of perioperative chemotherapy and operative and post-operative complications were collected. Then, according to recent World Health Organization (WHO) guidelines, the patients were grouped by age. Statistical analysis was performed using the software R (ver. 2.14.1). RESULTS: Hepatic resection was performed in 149 patients (21 patients in the very elderly group, 79 in the elderly group and 49 in the younger group). The three groups were comparable in terms of operative duration, transfusion rate, length of high-dependency unit (HDU) stay and post-operative hospital stay. The very elderly group showed a non-significant increase in post-operative morbidity. The 30-day and 60-day/inpatient mortality rates increased with age without any significant statistically difference between the three groups (very elderly group 4.8% and 4.8%; elderly group: 2.5% and 3.8%; and younger group 0% and 2%). At 5 years, the overall survival was 28.6% for very elderly patients (≥75 years), 33.3% for elderly patients (≥65 to <75 years) and 43.5% for younger patients (≤65 years). The 1-, 3- and 5-year disease-free survival was similar across the groups. CONCLUSIONS: Liver resection for CRLM in carefully selected patients above the age of 75 can be performed with acceptable morbidity and mortality rates, similar to those in younger patients. Moreover, the severity of CRLM in elderly patients is proven to be lesser than in younger patients. Thus, we can conclude that advanced chronological age cannot be considered a contraindication to hepatic resection for CRLM.
Authors: Alban Zarzavadjian Le Bian; Nicolas Tabchouri; Mostefa Bennamoun; Christophe Louvet; Candice Tubbax; Anthony Sarran; Marine Lefevre; Marc Beaussier; Frédéric Pamoukdjian; Philippe Wind; Brice Gayet; David Fuks Journal: Surg Endosc Date: 2019-01-22 Impact factor: 4.584
Authors: Dora Niedersüß-Beke; Manuel Orlinger; David Falch; Cordula Heiler; Gudrun Piringer; Josef Thaler; Wolfgang Hilbe; Andreas Petzer; Holger Rumpold Journal: Cancers (Basel) Date: 2021-04-26 Impact factor: 6.639
Authors: Ulf Kulik; Mareike Plohmann-Meyer; Jill Gwiasda; Joline Kolb; Daniel Meyer; Alexander Kaltenborn; Frank Lehner; Jürgen Klempnauer; Harald Schrem Journal: HPB Surg Date: 2018-10-21
Authors: Peter Schullian; Daniel Putzer; Michael A Silva; Gregor Laimer; Christian Kolbitsch; Reto Bale Journal: Front Oncol Date: 2019-09-19 Impact factor: 6.244